Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)
Completed · Phase 2
Conditions studied: Colorectal Cancer
In brief
This will be a randomized, open-label, multicenter, Phase II study with primary objectives to assess whether expression of select chemotherapy markers is associated with progression-free survival (PFS) in participants treated with bevacizumab plus leucovorin, 5-fluorouracil, and oxaliplatin (mFOLFOX6) or bevacizumab plus leucovorin, 5-fluorouracil, and irinotecan (FOLFIRI). The study population will consist of participants with first-line mCRC.
Key facts
- Study ID
- NCT01374425
- Run by
- Genentech, Inc.
- People needed
- 376
- Starts
- 2011-08-01
- Expected to finish
- 2015-07-01
- Last updated by the study team
- 2016-08-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed colorectal cancer (CRC) with at least one measurable metastatic lesion by RECIST Version 1.1
- Archival tumor tissue sample must be requested and available prior to study entry. If no archival tumor tissue sample is available, a fresh biopsy tissue sample must be obtained but should be discussed first with the medical monitor. A copy of the local pathology report must be submitted along with the specimens.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Participants with treated brain metastases are eligible for study participation. Participants may not receive ongoing treatment with steroids at Screening. Anticonvulsants (at stable dose) are allowed. Treatment for brain metastases may be whole-brain radiotherapy, radiosurgery, neurosurgery, or a combination as deemed appropriate by the treating physician. Radiotherapy and stereotactic radiosurgery must be completed at least 28 days prior to randomization.
- Female participants should not be pregnant or breastfeeding. Female participants with childbearing potential should agree to use effective, non-hormonal means of contraception during the study and for a period of at least 6 months following the last administration of study drugs. Female participants with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 7 days prior to randomization into the study.
- Male participants must agree to use effective contraception during the study and for a period of at least 6 months following the last administration of study drugs, even if they have been surgically sterilized.
You may not qualify if…
- Any prior systemic treatment for mCRC
- Adjuvant chemotherapy for CRC completed <12 months
- Evidence of Gilbert's syndrome or of homozygosity for the UGT1A1*28 allele
- Known positivity for human immunodeficiency virus (HIV)
- Malignancies other than mCRC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent
- Radiotherapy to any site for any reason within 28 days prior to randomization, except for palliative radiotherapy to bone lesions within 14 days prior to randomization
- Clinically detectable third-space fluid collections that cannot be controlled by drainage or other procedures prior to study entry
- Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
Where it is running
- Study site — Little Rock, Arkansas, United States
- Study site — Bellflower, California, United States
- Study site — Duarte, California, United States
- Study site — Fountain Valley, California, United States
- Study site — Fresno, California, United States
- Study site — Hayward, California, United States
- Study site — Los Angeles, California, United States
- Study site — Oakland, California, United States
- Study site — Pleasant Hill, California, United States
- Study site — Roseville, California, United States
- Study site — Sacramento, California, United States
- Study site — Sacramento, California, United States
- Study site — San Francisco, California, United States
- Study site — San Jose, California, United States
- Study site — Santa Clara, California, United States
- Study site — South San Francisco, California, United States
- Study site — Vallejo, California, United States
- Study site — Walnut Creek, California, United States
- Study site — Denver, Colorado, United States
- Study site — Stamford, Connecticut, United States
- Study site — Trumbull, Connecticut, United States
- Study site — Hollywood, Florida, United States
- Study site — Jacksonville, Florida, United States
- Study site — Miami, Florida, United States
- Study site — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.